Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Do not try this at home: patterns and outcomes of radiation dose de-escalation in p16-positive oropharyngeal carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer
10.3322/caac.21758 · 2023 · External reference
Human papillomavirus and survival of patients with oropharyngeal cancer
10.1056/nejmoa0912217 · 2010 · External reference
Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation dose
10.1172/jci194073 · 2025 · External reference
Evaluation of substantial reduction in elective radiotherapy dose and field in patients with human papillomavirus–associated oropharyngeal carcinoma treated with definitive chemoradiotherapy
10.1001/jamaoncol.2021.6416 · 2022 · External reference
Dose and volume de-escalation for human papillomavirus-positive oropharyngeal cancer is associated with favorable posttreatment functional outcomes
10.1016/j.ijrobp.2020.04.014 · 2020 · External reference
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
10.1016/s0140-6736(18)32752-1 · 2019 · External reference
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis
10.1200/jco.2007.14.8841 · 2008 · External reference
Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)
10.1200/jco.20.03128 · 2021 · External reference
Phase II trial of de-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma
10.1200/jco.19.01007 · 2019 · External reference
E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group
10.1200/jco.2016.68.3300 · 2017 · External reference
Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study
10.1016/s1470-2045(17)30246-2 · 2017 · External reference
Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: An ECOG-ACRIN Cancer Research Group trial (E3311)
10.1200/jco.21.01752 · 2022 · External reference
Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus–associated oropharynx squamous cell carcinoma
10.1200/jco.19.00463 · 2019 · External reference
Hypoxia-directed treatment of human papillomavirus-related oropharyngeal carcinoma
10.1200/jco.23.01308 · 2024 · External reference
Interim futility results of NRG-HN005, a randomized, phase II/III non-inferiority trial for non-smoking p16+ oropharyngeal cancer patients
10.1016/j.ijrobp.2024.08.014 · 2024 · External reference
NCCN guidelines® Insights: head and neck cancers, version 2.2025
10.6004/jnccn.2025.0007 · 2025 · External reference
Radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma: An ASTRO clinical practice guideline
10.1016/j.prro.2024.05.007 · 2024 · External reference
Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma
10.1016/j.radonc.2019.01.016 · 2019 · External reference
Radiotherapy dose and survival outcomes in human papillomavirus positive oropharyngeal cancer
10.1017/s0022215120001176 · 2020 · External reference
Concurrent immunoradiation for HPV-associated oropharyngeal squamous cell carcinoma
10.1007/s00405-022-07613-2 · 2023 · External reference
Using the National Cancer Database for outcomes research: A review
10.1001/jamaoncol.2016.6905 · 2017 · External reference
Changes in the 8th edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: Rationale and implications
10.1007/s11912-019-0799-x · 2019 · External reference
tableone: An open source Python package for producing summary statistics for research papers
10.1093/jamiaopen/ooy012 · 2018 · External reference
De-escalation for human papillomavirus-positive oropharyngeal cancer: A look at the prospective evidence
10.1007/s11912-025-01652-8 · 2025 · External reference
Long-term follow-up of E3311, an ECOG-ACRIN Cancer Research Group phase II trial of transoral surgery and risk-based adjuvant treatment in human papillomavirus-initiated oropharynx cancer
10.1200/jco-24-02550 · 2025 · External reference
De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial
10.1016/s1470-2045(25)00324-9 · 2025 · External reference
De-escalated management of HPV-positive oropharyngeal carcinoma: Improving outcomes with personalized approaches
10.1016/j.semradonc.2025.01.004 · 2025 · External reference
Early dynamics of circulating tumor HPV-DNA with neoadjuvant chemotherapy and response-adapted de-escalation in human papillomavirus-associated oropharyngeal cancer
10.1158/1078-0432.ccr-25-0152 · 2025 · External reference
De-escalation of adjuvant therapy in operatively managed HPV associated oropharyngeal carcinoma: Current status and future directions
10.1016/j.semradonc.2025.02.002 · 2025 · External reference
